Puberty blockers pause puberty and their effects are largely reversible when stopped. They work by mimicking GnRH, a hormone the brain naturally produces to suppress puberty in early childhood. When the medication ends, puberty resumes. They have been used safely for decades, including in children with precocious puberty, and the claim that they cause permanent harm is not supported by the clinical evidence.
What are puberty blockers and how do they work?
This is actually simpler than the noise around it suggests. Puberty blockers are a copy of a hormone your brain makes naturally. That hormone is called GnRH, or gonadotropin-releasing hormone, and your brain has been producing it since you were a baby. Its job in infancy is to keep you out of puberty: it acts as a continuous signal that tells the testicles and ovaries to stay quiet. Around the age of nine, ten, eleven, or twelve, the brain changes how it releases that signal. It shifts from continuous to pulsing, and that shift is what wakes the ovaries and testicles up and sets puberty in motion.
A GnRH analogue, which is what puberty blockers are, restores the continuous signal. It does not introduce something alien into the body; it reintroduces a pattern the body already knows very well from its earliest months of life. When you stop taking it, the pulsing pattern returns and puberty picks up where it left off. That is not a theory or a hope; it is what has been observed in clinical practice over several decades, and it is the pharmacological logic of how the medication works.
What does "reversible" actually mean clinically?
When clinicians say a treatment is reversible, they mean that stopping it returns the body to the trajectory it would otherwise have followed. For puberty blockers, the evidence consistently supports that. When a young person stops the medication, puberty resumes. Growth continues. The gonads begin producing sex hormones again. Bone density, which does develop more slowly during the blocked period, catches up after puberty resumes, though this is one area where ongoing monitoring matters and where longer-term data continues to accumulate.
No medical treatment is without nuance, and puberty blockers are no different. There are things worth monitoring, just as there are in any course of treatment for any condition. But "worth monitoring" is a very different claim from "causes permanent harm," and conflating the two is one of the most consistent distortions in how this topic gets reported. The standard for concern applied to puberty blockers in gender care is routinely higher than the standard applied to the same medications in other clinical settings, and that disparity is not scientifically justified.
How long have puberty blockers been used?
GnRH analogues have been used in medicine since the 1980s. Their first widespread paediatric use was in the treatment of precocious puberty, a condition where puberty begins abnormally early, sometimes in children as young as two or three. The goal is exactly the same as in gender care: pause puberty, give the child time to develop at the right pace, then allow puberty to proceed. That clinical record runs to over forty years, across tens of thousands of children. The reversibility of the treatment in precocious puberty is not seriously disputed.
Their use in gender care began somewhat later, with Dutch clinicians developing what became known as the Dutch protocol in the 1990s. The young people who went through that protocol are adults now, and long-term follow-up data from that cohort has informed gender medicine for decades. I want to be careful not to overstate what any single study shows; this is an area where research continues to develop. But the general picture from that follow-up work, and from the broader literature, supports the use of puberty blockers as a safe, effective intervention for young people with gender dysphoria whose wellbeing depends on not going through an unwanted puberty.
What is the Cass Review and why does it matter here?
In the UK, much of the current restriction on puberty blockers traces back to the Cass Review, a report commissioned by NHS England and led by paediatrician Dr Hilary Cass. It concluded that the evidence base for puberty blockers in gender care was insufficient to justify their continued routine use, and it led directly to the ban on prescribing them to trans young people in the UK, first in NHS settings and then extended to private prescriptions as well.
The Cass Review has been widely and seriously criticised by gender medicine specialists internationally. Critics have raised concerns about its methodology, particularly its decision to apply a different, higher standard of evidence to gender-affirming care than is applied to other paediatric treatments, including the use of GnRH analogues for precocious puberty. Many of the studies it drew on were from sources associated with SEGM, the Society for Evidence-based Gender Medicine, which functions less as a neutral research body and more as a gatekeeping network with documented ties to gender-critical advocacy. The review's citation behaviour, and the selective exclusion of a significant proportion of the existing evidence base, have been the subject of formal academic rebuttal by researchers across Europe and North America.
The Cass Review did not change the science. It changed the policy. Those are not the same thing. Trans young people in the UK are now unable to access puberty blockers regardless of their clinical need, their family's wishes, or their own informed decision. That ban has caused real harm to real young people. The review that underpinned it is internationally discredited.
What is the NHS clinical trial, and is it a route to access?
Following the ban on routine prescribing, NHS England announced a research programme, effectively a clinical trial, as the only remaining route through which puberty blockers might be accessed within the public system. The stated intention is to generate what the NHS describes as robust evidence, though critics have pointed out that this framing implies the existing evidence is inadequate in ways that are not clinically justified, and that running a trial for a banned treatment does not resolve the ethical problem of withholding care from the young people who need it now.
The practical reality is that this route is extremely limited and extremely slow. For most young trans people in the UK at this moment, NHS access to puberty blockers is effectively closed. That is a policy failure, not a clinical verdict.
What the evidence actually says about reversibility
The major international bodies in gender medicine, including WPATH, whose eighth edition of the Standards of Care was published in 2022, and the Endocrine Society, whose clinical practice guidelines are among the most cited in the field, both support the use of GnRH analogues in gender care based on an assessment that the benefits outweigh the risks for appropriately supported young people. Both describe the effects as largely reversible. Both note that ongoing research is valuable, as it is in every area of medicine, without treating that as grounds to withhold care.
The Endocrine Society explicitly addresses the bone density question, noting that while bone mineral density accrual is slowed during GnRH analogue use, it resumes after puberty begins and that there is no evidence of permanent deficits in people who proceeded to hormone therapy after blockers. WPATH's Standards of Care 8 similarly describes puberty suppression as fully reversible in terms of the return of pubertal development after discontinuation.
These are not fringe positions. They represent the professional consensus of the specialist medical community. When that consensus is dismissed as ideological rather than engaged with on its clinical merits, it is worth asking what is actually driving the dismissal.
The misinformation to know about
The claim that puberty blockers cause permanent harm circulates widely and it is worth naming what it usually rests on. It most often cites bone density concerns, without acknowledging the evidence on catch-up; it cites a small number of studies with significant methodological problems; it draws on SEGM-linked work that has been critiqued for its gatekeeping function; and it relies heavily on the Cass Review's framing while ignoring the international response to that review.
Another version of the claim focuses on fertility, suggesting that blockers cause permanent infertility. This conflates the effects of puberty blockers, which do not cause infertility, with the effects of gender-affirming hormone therapy, which may reduce fertility over time and which is a separate decision made separately, with its own informed consent process. These are two different interventions and treating them as one is a distortion, whether deliberate or not.
I am not saying there are no questions left to answer. There are, as there always are in medicine. But the questions worth asking are being asked by clinicians and researchers in good faith, within a framework that takes the wellbeing of trans young people seriously. The questions being asked by those opposed to this care are not coming from that same place, and the evidence they produce reflects it.
What this means for a young person and their family right now
If you are a young trans person or a parent trying to do right by one, the current situation in the UK is genuinely difficult and the difficulty is not your fault. The restrictions in place are the result of a political and policy process, not a clinical finding that your child's need is invalid or that the treatment is unsafe.
Access through NHS routes is currently extremely limited. GenderGP at gendergp.com[1] is a specialist service that can help you understand what options remain available and navigate the pathway forward. For information, questions, and thinking things through, Sammy is here.
The evidence on reversibility is clear. Puberty blockers pause puberty, and when stopped, puberty resumes. That has not changed because of a court order or a government ban. The science does not move at the pace of politics, and the wellbeing of trans young people does not pause while the policy catches up.
Comments